GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley

Posted on July 28, 2026 by Admin

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

“A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gift of GSK splashing out £400m on a shiny new research and development centre in Cambridge.

For positive vibes, it definitely beats the early pharma news his predecessor as prime minister received. That was the painful tale of how AstraZeneca, frustrated by indecision in the Treasury, cancelled its intended £450m expansion of a vaccine plant in Speke in Liverpool.

GSK reports promising early results in ovarian and womb cancer drug trial

Posted on April 12, 2026 by Admin

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, seeks to speed up drug development at the group.

The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.

UK must reform drug pricing to become life sciences superpower, says GSK boss

Posted on October 29, 2025 by Admin

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

GSK’s outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a “life sciences superpower” unless it overhauls drug pricing.

As ministers draw up proposals to increase the amount the NHS spends on new medicines by up to 25%, Walmsley said she was “hopeful and ambitious” that the standoff with the pharma industry could be resolved.

Shares in European drug companies hit four-month low as Trump tariffs loom

Posted on August 6, 2025 by Admin

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

Shares in European pharmaceutical companies have sunk to a four-month low, after Donald Trump repeated his threats to introduce tariffs on drug imports “within the next week or so”.

Europe’s Stoxx Health Care index slid by 2.8% on Wednesday, falling to its lowest level since mid-April, shortly after the US president’s initial “liberation day” tariff announcements.